Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-103 + Venetoclax in R/R T-ALL/T-LBL
NCT05464836Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of limantrafin in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2023; status: terminated.
02
Drugs
limantrafin
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05464836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464836.